Introduction: Among patients with chronic
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INTRODUCTION
Exacerbations have a deleterious effect on the morbidity and mortality of patients with chronic obstructive pulmonary disease (COPD) [1] by increasing hospitalization [2] , worsening lung function [3] and health-related quality of life, and decreasing survival [4] . As such, the prevention of exacerbations is an important goal of COPD therapy [5] , the importance of which is reflected in the current Global Initiative for Chronic Obstructive Lung Disease (GOLD) document on the management of COPD [6] .
The frequency of exacerbations increases in parallel with the severity of COPD [7] . In the Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE Ò ) (ClinicalTrials.gov #NCT00292552)
observational study of patients with COPD, exacerbation rate was shown to increase with GOLD staging, such that 22% of patients with GOLD Stage II disease had two or more exacerbations during 1 year of follow-up, whereas 47% of patients with GOLD Stage IV disease had frequent exacerbations over the same period. Across all GOLD stages, the single best predictor of future episodes was prior exacerbations [8] . salmeterol (50 lg via a hydrofluoroalkanepressurized metered-dose inhaler twice daily) on the incidence of moderate and severe exacerbations in 7376 patients with COPD and a history of exacerbations in the preceding year [9] . The POET-COPD trial showed that, among the total patient population, tiotropium as compared with salmeterol (1) increased the time to the first exacerbation, (2) significantly increased the time to the first severe exacerbation, and (3) reduced the annual number of moderate or severe exacerbations [9] . However, the impact of tiotropium and salmeterol specifically on patients at low or high risk of exacerbations has not been established.
The current study therefore investigated the effect of tiotropium and salmeterol on exacerbations in patients considered to be at a low or high risk for exacerbations (GOLD guidelines 2014 classification) and frequent/ infrequent exacerbators (ECLIPSE study criteria) during a 1-year treatment period in a post hoc analysis of patients in the POET-COPD trial.
METHODS

Study Design
POET-COPD was a 1-year, randomized, doubleblind, double-dummy, parallel-group trial that analyzed the effect of tiotropium 18 lg once daily or salmeterol 50 lg twice daily on moderate to severe exacerbations in patients with COPD [9] . The primary endpoint of the trial was time to first moderate or severe exacerbation. Secondary and safety endpoints included time to event, number of events, serious adverse events, and mortality. An exacerbation was defined as an increase in, or new onset of, at least two respiratory symptoms (cough, sputum, dyspnea, wheezing, chest tightness) with at least one symptom lasting for C3 days and leading the patient's attending physician to initiate treatment with systemic corticosteroids and/or antibiotics (moderate exacerbation) or request hospitalization (severe exacerbation) [8, 10] 
Statistical Analysis
The statistical tests were designed to test the hypothesis that tiotropium had a greater efficacy than salmeterol in preventing future exacerbations. Post hoc analyses were performed by the subgroups that were low/ high risk at baseline and based on collected COPD characteristics, including hospitalization due to an exacerbation and medication use.
A Cox proportional hazards regression model was used for time-to-exacerbation analyses.
Hazard ratios (HR) and p values were based on This article is based on previously conducted studies and does not involve any new studies of human or animal subjects performed by any of the authors.
RESULTS
The baseline characteristics of patients stratified according to low/high exacerbation risk is summarized in Table 1 . Except for baseline lung function and baseline ICS use, patients in the low-risk (n = 2610) and high-risk (n = 4284) groups were balanced. Within the risk subgroups, there were no clinically relevant differences in the baseline characteristics of patients in the tiotropium and salmeterol groups (data not shown).
Time to First COPD Exacerbation
Using the GOLD 2013 risk classification for exacerbations, tiotropium reduced the risk of a COPD exacerbation compared with salmeterol in patients classified as being at high risk or low risk for exacerbations (Fig. 1) Table 2) . Whether or not patients were on background ICS at baseline did not impact these results (Table 3) .
Number of COPD Exacerbations (Adjusted Annual Rates)
Tiotropium significantly reduced the number of COPD exacerbations compared with salmeterol in patients classified as being at high risk for (Fig. 2) . In patients classified as being at low risk for exacerbations, there was a borderline significant reduction with tiotropium in the number of COPD exacerbations compared with salmeterol (RR 0.89; 95% CI 0.76-1.05; p = 0.1768; adjusted annual rates = 0.48 and 0.54 for tiotropium and salmeterol, respectively) (Fig. 2) . The post hoc subgroup analysis comparing both high-and low-risk patients who were or were not receiving ICS at baseline showed similar trends towards tiotropium reducing the number of COPD exacerbations; however, in high-risk patients receiving ICS at baseline, this was a numerical difference only (Fig. 3) .
Treatment-Induced Shifts in Patient Risk Classification
Comparing patients at low versus high risk for exacerbations before and after 1 year's treatment with either tiotropium or salmeterol showed that treatment resulted in a shift in the ratio (low/high exacerbation risk) from 0.62 to 4.98 and from 0.60 to 4.25 for treatment with tiotropium and salmeterol, respectively (Table 4) . When using the infrequent versus frequent for exacerbations definition, shifts in the ratio (infrequent/frequent exacerbations) were larger (from 0.82 to 6.44 and from 0.78 to 5.80 for treatment with tiotropium and salmeterol, respectively) ( Table 4 ). The risk of remaining in the high-risk subgroup for exacerbations after 1 year of treatment was statistically lower in the tiotropium group than in the salmeterol group (RR 0.89; 95% CI 0.80-1.00; p = 0.0478) ( Table 5 ). The risk of patients who were in the low-risk subgroup for exacerbations in the previous year being considered at high risk for exacerbations after 1 year's treatment was statistically lower in the tiotropium group compared with salmeterol (RR 0.87; 95% CI 0.71-1.07; p = 0.1968) ( Table 5) . 
DISCUSSION
This post hoc analysis of the POET-COPD trial, which investigated the effect of tiotropium and salmeterol on exacerbations in patients considered to be at a low or high risk for exacerbations during the 1-year treatment period, had two main findings. First, it confirmed the higher efficacy of tiotropium compared with salmeterol in prolonging the time to first COPD exacerbation and reducing the number of COPD exacerbations in patients considered to be at low risk, as well as in those considered to be at high risk, for exacerbations.
Second, our results show that background ICS usage at baseline, or lack thereof, had no impact Fig. 2 Number of COPD exacerbations after treatment by patient exacerbation risk classification. CI confidence interval, COPD chronic obstructive pulmonary disease, RR risk ratio [8] or recent GOLD [6] definitions are applied. In those patients classified as being at low risk for exacerbations, the results were borderline significant in favor of tiotropium, whereas in the high-risk group, this difference was statistically significant in favor of tiotropium. This might be explained by a lower number of exacerbations in the low-risk group.
It is noteworthy that the comparable effect observed from treatment with tiotropium versus salmeterol on COPD exacerbations does not appear to be influenced by the concomitant use of background ICS, although the risk ratio is more favorable for tiotropium when compared with salmeterol in both low-and high-risk exacerbator groups that were not using ICS.
Not only did our results show that treatment with tiotropium or salmeterol resulted in a higher proportion of patients shifting from the high-risk (frequent) to the low-risk (infrequent) exacerbator group, but also that treatment prevented patients at low risk of exacerbations from transitioning into the high-risk group.
Many studies have shown that intervention with pharmacotherapy confers benefit to patients with COPD by reducing exacerbations or prolonging the time to first exacerbation [11] [12] [13] [14] ; however, few have successfully demonstrated that pharmacotherapy can positively influence the future risk of patients experiencing exacerbations [15] . As observed in other interventional trials both in COPD and asthma [13, 16] , the overall shift in the exacerbation frequency prior to enrollment versus randomized treatment is remarkable and somehow surprising, particularly in comparison to the relative stability of the phenotype in an observational setting [17] .
While insufficient background COPD treatment prior to inclusion may at least partially explain this strong shift, other factors may also be relevant such as the definition and documentation of exacerbations [18] (e.g., post
hoc for history of exacerbations vs.
prospectively on trials) as well as recall or reporting of exacerbations [19] .
We speculate that by intervening early in the disease process, it may therefore be possible to minimize deleterious effects associated with increased frequency and severity of exacerbations in patients with COPD.
A limitation of the current study is that the POET-COPD trial was not designed to evaluate the effect of tiotropium specifically in different exacerbator phenotypes, nor was it designed to evaluate the effect of tiotropium on mitigating future risk for exacerbations. However, the detailed information regarding exacerbation history before enrollment and subsequently recorded over the course of the study, the large number of patients that participated, and the careful attention to study outcomes provides confidence in the results.
CONCLUSION
The results from the current study provide further evidence for intervention with tiotropium as maintenance therapy in COPD patients both at low or high risk for exacerbations. 
